Bicycle Therapeutics plc American Depositary Shares (BCYC) is a publicly traded Healthcare sector company. As of May 21, 2026, BCYC trades at $4.47 with a market cap of $304.38M and a P/E ratio of -1.22. BCYC moved +1.72% today. Year to date, BCYC is -33.13%; over the trailing twelve months it is -48.06%. Its 52-week range spans $4.24 to $28.67. Analyst consensus is buy with an average price target of $13.57. Rallies surfaces BCYC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bicycle Therapeutics Depioritizes Zelenectide, Cuts Costs 50% and Extends Runway to 2030: Bicycle Therapeutics selected a 6mg zelenectide dose in metastatic urothelial cancer, achieving a 65% physician-assessed ORR and 58% BICR-confirmed ORR. The company will turn Duravelo-2 into a Phase 2 trial, deprioritize the zelenectide program, slash expenses by 50% through a 30% workforce cut and extend cash runway to 2030.
| Metric | Value |
|---|---|
| Price | $4.47 |
| Market Cap | $304.38M |
| P/E Ratio | -1.22 |
| EPS | $-3.62 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.67 |
| 52-Week Low | $4.24 |
| Volume | 7 |
| Avg Volume | 0 |
| Revenue (TTM) | $28.34M |
| Net Income | $-250.66M |
| Gross Margin | 0.00% |
8 analysts cover BCYC: 0 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.57.